Search the Newsreel

RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?

RxSight (RXST) shares increased by 6.1% to $5.57, driven by high trading volume and investor optimism regarding an upcoming leadership transition. Aziz Mottiwala is set to become the new President and CEO on July 20, 2026. Despite a projected quarterly loss of $0.21 per …

Insight Enterprises schedules before-market results and 9 a.m. call

Insight Enterprises, Inc. (Nasdaq: NSIT) announced it will release its second-quarter 2026 financial results prior to market open on August 6, 2026. The company will also host a conference call and live webcast at 9:00 a.m. ET on the same day to discuss the …

Medicare expands coverage for transplant monitoring test, boosting Insight Molecular Diagnostics' GraftAssure adoption.

Medicare has expanded its coverage for donor-derived cell-free DNA (dd-cfDNA) testing, which will increase patient access and testing frequency for kidney and heart transplant recipients. This policy change will benefit Insight Molecular Diagnostics (iMDx) and its GraftAssure transplant monitoring assays, supporting their strategy for …

Alcon (SWX:ALC) After The RxSight Deal Is The Growth Story Already Priced In

Alcon (SWX:ALC) has gained attention after a collaboration with RxSight for adjustable presbyopia-correcting intraocular lenses, leading to recent share price momentum. However, despite a "25.7% Undervalued" narrative targeting a fair value of CHF76.62 due to new product launches and M&A, the current P/E ratio …

iMDx Highlights Expanded Medicare Coverage for Donor-Derived Cell-Free DNA Transplant Testing

Insight Molecular Diagnostics Inc. (iMDx) announced that Medicare has expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care, a move expected to boost the commercial adoption of its GraftAssure™ assays. The new MolDX policy clarifies reimbursement guidelines, increases testing frequency for kidney …

Keysight Technologies Inc. stock underperforms Thursday when compared to competitors

Keysight Technologies Inc. (KEYS) shares declined 3.08% on Thursday, closing at $312.76. This underperformance occurred during a negative trading session for the broader market, with both the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. This marks the second consecutive day …

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Insight Molecular Diagnostics Inc. (iMDx) has announced a favorable new Medicare policy that significantly expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. This policy clarifies reimbursement guidelines, increases testing frequencies for transplanted organ patients, and cites iMDx's research, bolstering the commercial …

Keysight Technologies (KEYS) Could Be 18% Undervalued As ESA Project Fuels Growth Narrative

Keysight Technologies (KEYS) has secured a three-year contract with the European Space Agency to develop secure, blockchain-enabled anomaly detection for 5G non-terrestrial networks. Despite a recent short-term pullback, the company's stock has shown strong long-term momentum. Analysts believe KEYS could be 18% undervalued, citing …

Foresight Autonomous Holdings Ltd. American Depositary Shares (FRSX) Stock Price, News & Analysis

This article provides a comprehensive overview of Foresight Autonomous Holdings Ltd. American Depositary Shares (FRSX), including its current stock price, key statistics, company overview, and MarketRank™ analysis. FRSX, an Israel-based technology company specializing in advanced vision and sensing systems for driver assistance and autonomous …

RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO

RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as president and CEO, effective July 20, 2026. Current CEO Ron Kurtz, MD, will transition to chief medical officer and resign from the board of directors, with Mottiwala joining the board. This change follows …

RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com

RxSight, Inc. has announced Aziz Mottiwala as its new President and CEO, effective July 20, replacing Ron Kurtz, who will become Chief Medical Officer. This leadership change occurs as RxSight's stock has seen a significant decline, though InvestingPro analysis suggests it may be undervalued. …

RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition, appointing Aziz Mottiwala as President and CEO, effective July 20, 2026. Former CEO Ron Kurtz, M.D., will transition to Chief Medical Officer. Mottiwala's compensation package includes a $750,000 base salary, guaranteed cash bonus, and $14 million …

RxSight CEO Ron Kurtz to Continue as Chief Medical Officer

RxSight (NASDAQ: RXST) announced a leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer. Ron Kurtz, M.D., the current CEO, will transition to Chief Medical Officer, focusing on technology and clinical development, and will resign from the Board. …

Press Release: RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight has announced significant leadership changes, appointing Aziz Mottiwala as the new Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer, effective immediately. Mr. Mottiwala previously served as Chief Commercial Officer, while Dr. Kurtz was a co-founder and former CEO of the …

USU4570UAA0 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the USU4570UAA0 bond issued by Insight Enterprises, Inc. The bond has a coupon rate of 6.63% and the next payment is scheduled for November 16, 2026. It highlights essential data regarding interest rates and payment schedules for …

Chris Tanner leaves Foresight Environmental Infrastructure for different role within Foresight Group

Foresight Environmental Infrastructure confirms portfolio management continuity amid reshuffle

Sight Sciences Q1 2026 Earnings: EPS Misses Estimates, Stock Edges Higher - Annual Earnings Summary

Insight Digital Partners II (DYOR) Holds Steady Near Support Amid Low Volatility - Continuation Pattern Picks

Is Strengthening Drone‑Defence Demand Altering The Investment Case For Elsight (ASX:ELS)?

IMDX Forecast — Price Target — Prediction for 2027

IMDX Q1 2026 Earnings: Narrower-than-expected loss drives stock surge - Trough Earnings Signal

Panmure Liberum lifts Foresight Environmental Infrastructure target to 92p on growth progress

Keysight sits 1.8% below its high as activity pressure fades beneath a 44-week Trend Signal

Keysight’s weekly advance keeps the Scientific & Technical Instruments stock near the top of its one-year range, but the latest move came on lighter participation and a cooling activity-pressure read.

Elsight (ELS.AX) Stock: 693% Revenue Growth, Buy Rating and A$8.10 Target Put This ASX Tech Innovator on Investor Radar

Did Insight’s New AI Cybersecurity Service and Credit Tweaks Just Reframe Insight Enterprises' (NSIT) Growth Story?

FRSX Q3 2021 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Management Tone Analysis

Sight Sciences Inc. (SGHT) Nears Support as Shares Edge Lower - Profit Surge Picks

Insight Digital Partners II (DYOR) Holds Steady: Narrow Range Suggests Consolidation - Symmetrical Triangle

Keysight Technologies Q2 2026: $2B in Orders and 69% EPS Growth, Is the Stock Already Priced for It at $344?

Insight Digital Partners II 1Q 2026: Net income $1.26M, EPS $0.05— 10-Q Summary

Does Insight’s Margin-Led Q1 Earnings Beat And FMR Stake Shift The Bull Case For NSIT?

Insight Enterprises (NASDAQ:NSIT) Posts Better-Than-Expected Sales In Q1 CY2026, Stock Soars

Insight Enterprises (NSIT) Beats Q1 Earnings Estimates

Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences, Inc. Q1 2026 Earnings Call Summary